Related Experiment Video
Updated: Jun 20, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
Published on: January 31, 2020
The anti-inflammatory potential of nicotinamide (vitamin B3) in JIA: modulating Treg numbers and function with
Lotte Nijhuis1, Rianne C Scholman1, Arief Lalmohamed2
1Center for Translational Immunology, University Medical Center Utrecht, Lundlaan 6, 3584CX, Utrecht, 3584 EA, The Netherlands.
Background:
Juvenile Idiopathic Arthritis (JIA) is the most common rheumatic disease in children and is characterized by chronic joint inflammation driven by immune dysregulation. A disturbed regulatory T (Treg) cell-effector T cell axis has been demonstrated in these patients which contributes to a dysregulated immune tolerance in JIA. Therefore, strategies to enhance Treg numbers and suppressive capacity to restore immune homeostasis represent a promising therapeutic approach. Nicotinamide (NAM), a form of vitamin B₃ and precursor of nicotinamide adenine dinucleotide (NAD⁺), has emerged as an immunomodulator capable of promoting Treg cell function.
Methods:
Here, we investigate the effects of NAM on Treg percentages and suppressive capacity in mononuclear cells derived from peripheral blood (PBMCs) and synovial fluid of JIA patients (SFMCs). In an exploratory pilot phase II clinical study, NAM concentrations were measured in paired blood plasma and SF from 6 JIA patients after oral administration of daily 1.8 g/m2 for three days.
Results:
NAM treatment significantly increased the proportion of FOXP3-expressing CD4+ T cells in both PBMCs and SFMCs and Treg suppressive capacity in PBMCs from healthy controls in vitro. Comparable NAM concentrations were detected in plasma and SF following oral administration, demonstrating its ability to penetrate the inflamed joint environment.
Conclusion:
Given its established safety in both adults and children, NAM represents a promising future candidate for adjunctive therapy in JIA by restoring the balance between regulatory and effector T cells. Further clinical and mechanistic studies are warranted to define optimal dosing regimens and its place in the long-term treatment strategy of JIA.
Trial Registration:
Assessing penetration of high dose nicotinamide (Vitamin B3) in synovial fluid. EudraCT Number: 2018-002245-11, start date Jan 16th, 2019.
Related Concept Videos
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
The JAK-STAT Signaling Pathway
Acute Inflammation III: Local and Systemic Effects
Inflammation
Inflammatory Response I: Vascular and Cellular
